Cancer Research

Are Piezoelectric Nanozymes the Future of Cancer Therapy?
Research & Development Are Piezoelectric Nanozymes the Future of Cancer Therapy?

Current clinical advancements in nanomedicine prioritize the development of materials that can unmask tumor antigens to the immune system through precise cell lysis. This strategic shift reflects a broader recognition that conventional treatments like chemotherapy often falter because they cannot

FAU Researchers Use Quantum AI to Predict Lung Cancer Cases
Tech & Innovation FAU Researchers Use Quantum AI to Predict Lung Cancer Cases

The persistence of environmental noise and decoherence remains a primary technical hurdle when transitioning quantum diagnostic models from simulations to physical processors. Florida Atlantic University (FAU) researchers have successfully navigated these complexities to achieve a significant

Can mRNA Monobodies Treat Undruggable Cancers?
Tech & Innovation Can mRNA Monobodies Treat Undruggable Cancers?

Transcription factors act as biological switches that, when stuck in the 'on' position, trigger the rapid and unregulated cell division characteristic of malignant tumors. For decades, these pivotal components of cellular machinery have remained largely out of reach for modern pharmacology, leading

Can CAR T-Cell Therapy Cure Hairy Cell Leukemia?
Research & Development Can CAR T-Cell Therapy Cure Hairy Cell Leukemia?

Standard retreatment for relapsed hairy cell leukemia often involves cumulative chemotherapy toxicity, prompting the search for alternative therapies that do not carry the risk of graft-versus-host disease. Recent advancements in hematologic oncology have ushered in a new era of precision medicine,

M13 Bacteriophage Nanovaccine – Review
Research & Development M13 Bacteriophage Nanovaccine – Review

Biological engineers have spent decades searching for a nanoscale Swiss Army knife that can simultaneously alert the immune system and deliver precision-guided payloads to malignant cells without the systemic toxicity typically associated with traditional chemotherapy. The M13 bacteriophage, a

EU Approves Trastuzumab Deruxtecan for Early Breast Cancer
Research & Development EU Approves Trastuzumab Deruxtecan for Early Breast Cancer

Approximately 20 percent of all breast cancer diagnoses are classified as HER2-positive, a subtype historically associated with aggressive growth and poor clinical outcomes. The landscape of HER2-positive early breast cancer treatment has undergone a significant transformation with the European

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later